--:--:-- ET
New York 62°F Partly cloudy Los Angeles 78°F Sunny Chicago 55°F Windy
Subscribe
U.S. Edition Est. 2026 Nov. 20, 2026

US News America

Independent reporting for a changing America

Breaking
Health

HHS Commits Up to $4.9 Million to Ibogaine Research for PTSD and Opens $20 Million Program for Ketamine and Psilocybin

The Health Department announced funding to prepare the psychedelic drug ibogaine for clinical trials as a treatment for post-traumatic stress disorder in veterans, along with a separate research network for ketamine, esketamine and psilocybin.

A researcher in a white lab coat and blue gloves holding a small glass vial up to the light in a bright laboratory, seen from behind.

The Department of Health and Human Services will spend up to $4.9 million to prepare the psychedelic drug ibogaine for clinical trials as a possible treatment for post-traumatic stress disorder in veterans, Health Secretary Robert F. Kennedy Jr. announced on Thursday.

The money will come through the Advanced Research Projects Agency for Health, known as ARPA-H, over five years. It will pay for the groundwork needed before trials can begin: preparing applications to the Food and Drug Administration, securing clinical-grade ibogaine, and building a way to manufacture the drug in the United States. The department also opened a separate $20 million program through the National Institute of Mental Health to build a research network for rapid-acting drugs such as ketamine, esketamine and psilocybin. Winners of those awards will be named in the summer of 2027.

Kennedy announced the funding the day after Veterans Day, joined by leaders from the Department of Veterans Affairs. “Veterans kept their promise to this country. We must keep ours,” Kennedy said. “Veterans have told us ibogaine changed their lives. Their experiences demand serious scientific investigation.”

A quiet counseling office with two empty beige armchairs facing each other beside a large window, with a small wooden side table between them.

What the funding covers

Two research teams will carry out the ibogaine work. One, led by the Mark Cuban Cost Plus Drug Company, will set up the regulatory, clinical, chemical and engineering basis for a domestically made, single-molecule ibogaine hydrochloride product. The other, Beond Inc., will supply clinical data on safety, dosing, efficacy and how long any effect lasts. All award winners will make their research data public, the department said.

The department was clear about the limits. The awards do not pay for patient treatment or research on human subjects, do not authorize clinical trials, and do not amount to FDA approval. More ARPA-H awards are expected, including one aimed at substance use disorders that Kennedy said should be announced by the end of 2026, according to Reuters.

Glass beakers, test tubes and small medicine vials arranged on a clean bench in a research laboratory.

Safety risks remain

Ibogaine carries serious safety risks, including heart rhythm problems that can be life threatening, the department said. Any future studies must screen participants, monitor their hearts and use independent safety oversight, alongside the work of testing whether the drug helps.

The announcement follows President Donald Trump’s April directive to speed up research into psychedelic treatments. Trump set aside $50 million in April for ibogaine research, Reuters reported. If ibogaine is developed and wins FDA approval, the department said its goal is to price it at the cost of production plus a fair margin, and to publish research findings whether they show benefit, no benefit or harm.

Veterans in crisis, and anyone concerned about a veteran, can call 988 and press 1 to reach the Veterans Crisis Line.

A modern multi-story hospital building with an American flag on a pole in front, surrounded by trees and a paved walkway under a cloudy sky.

Reporting based on coverage by the U.S. Department of Health and Human Services and Reuters.